[Current and prospective issues about adult asthma]

Rev Mal Respir. 2015 Jun;32(6):629-38. doi: 10.1016/j.rmr.2015.01.002. Epub 2015 Jul 9.
[Article in French]

Abstract

The management of asthma treatment is likely to change in coming years, with the development of a more personalized approach. Biological therapies targeting Th2 cytokines (IL-4, IL-5 and IL-13) offer new treatment pathways for patients with severe asthma and high Th2 activity. Bronchial thermoplasty is the only treatment for severe asthma that could provide a long standing effect, but many questions still remain and its use is restricted to clinical research. Weight loss should be a goal during long-term management of obese asthmatics. Involvement of a new inflammatory pathway including IL-1 and IL-17 in a murine model of obesity and asthma may lead to new therapies in this subgroup of asthmatics.

Keywords: Anticorps monoclonal; Asthma; Asthme; Monoclonal antibody; Obesity; Obésité; Thermoplastie; Thermoplasty.

Publication types

  • Review

MeSH terms

  • Abatacept / therapeutic use
  • Adult
  • Anti-Asthmatic Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Asthma / complications
  • Asthma / immunology
  • Asthma / therapy*
  • Humans
  • Laser Coagulation / adverse effects
  • Laser Coagulation / methods
  • Lymphocytes / drug effects
  • Lymphocytes / immunology
  • Obesity / complications
  • Obesity / therapy
  • Therapies, Investigational* / adverse effects
  • Therapies, Investigational* / trends

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • dupilumab
  • Abatacept